Activity of intraarterial carboplatin as a single agent in the treatment of newly diagnosed extremity osteosarcoma

Página do item simplificado
dc.contributor.authorPetrilli, Antonio Sergio [UNIFESP]
dc.contributor.authorKechichian, Rita [UNIFESP]
dc.contributor.authorBroniscer, Alberto [UNIFESP]
dc.contributor.authorGarcia, Reynaldo Jesus [UNIFESP]
dc.contributor.authorTanaka, Cristiana [UNIFESP]
dc.contributor.authorFrancisco, J. [UNIFESP]
dc.contributor.authorLederman, Henrique [UNIFESP]
dc.contributor.authorOdone Filho, Vicente
dc.contributor.authorCamargo, Olavo Pires de
dc.contributor.authorBruniera, Paula
dc.contributor.authorPericles, Pedro
dc.contributor.authorConsentino, Elio
dc.contributor.authorOrtega, Jorge A.
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionFac Med Santa Casa São Paulo
dc.date.accessioned2016-01-24T12:30:51Z
dc.date.available2016-01-24T12:30:51Z
dc.date.issued1999-08-01
dc.description.abstractBackground. Chemotherapy has dramatically improved the rates of cure and survival of patients with localized and metastatic osteosarcoma. Nonetheless, the number of chemotherapeutic agents active against osteosarcoma is limited to doxorubicin, cisplatin, high-dose methotrexate, and ifosfamide. Carboplatin, a cisplatin analogue, has been tested as a single agent in patients with recurrent osteosarcoma or as part of multiagent chemotherapy in newly diagnosed patients. Procedure. We tested the activity and toxicity of two cycles of intraarterial carboplatin as a window therapy (600 mg/m(2) per cycle) in 33 consecutive patients with extremity osteosarcoma before the start of multiagent chemotherapy. Response was based on clinical (tumor diameter, local inflammatory signs, and range of motion) and radiological parameters (plain local films and arteriographic studies prior to drug administration). Results. Patients' age ranged between 8 and 18 years (median age 13 years). Primarytumor originated from the femur (15 patients), tibia (10 patients), fibula (4 patients), humerus (3 patients), and calcaneus (1 patient). Only 7 patients (21%) had metastatic disease at diagnosis (5 in the lung and 2 in other bones). A favorable clinical and radiological response was documented in 81% and 73% of the patients, respectively. Clinical and radiological progression occurred in 120% and 9% of the patients, respectively. Seventeen of the patients remain alive and disease-free. Survival and event-free survival at 3 years for nonmetastatic patients are 71% (SE = 9%) and 65% (SE = 9%), respectively; for metastatic patients, the figures are 17% (SE = 15%) and 14% (SE = 13%), respectively. Conclusions. We conclude that carboplatin is an active agent in the treatment of newly diagnosed extremity osteosarcoma. (C) 1999 Wiley-Liss, Inc.en
dc.description.affiliationUniversidade Federal de São Paulo, Dept Pediat, São Paulo, Brazil
dc.description.affiliationUniversidade Federal de São Paulo, Dept Orthoped, São Paulo, Brazil
dc.description.affiliationUniversidade Federal de São Paulo, Dept Radiol, São Paulo, Brazil
dc.description.affiliationUniv São Paulo, Dept Orthoped, São Paulo, Brazil
dc.description.affiliationFac Med Santa Casa São Paulo, Dept Pediat, São Paulo, Brazil
dc.description.affiliationFac Med Santa Casa São Paulo, Dept Orthoped, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Dept Pediat, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Dept Orthoped, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Dept Radiol, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent71-75
dc.identifierhttps://doi.org/10.1002/(SICI)1096-911X(199908)33:2<71::AID-MPO2>3.0.CO;2-T
dc.identifier.citationMedical and Pediatric Oncology. New York: Wiley-liss, v. 33, n. 2, p. 71-75, 1999.
dc.identifier.doi10.1002/(SICI)1096-911X(199908)33:2<71::AID-MPO2>3.0.CO;2-T
dc.identifier.issn0098-1532
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/26120
dc.identifier.wosWOS:000081495500002
dc.language.isoeng
dc.publisherWiley-Blackwell
dc.relation.ispartofMedical and Pediatric Oncology
dc.rightsAcesso restrito
dc.rights.licensehttp://olabout.wiley.com/WileyCDA/Section/id-406071.html
dc.subjectOsteosarcomaen
dc.subjectExtremity tumorsen
dc.subjectCarboplatin (CBDCA)en
dc.subjectChildhood canceren
dc.subjectAdolescentsen
dc.titleActivity of intraarterial carboplatin as a single agent in the treatment of newly diagnosed extremity osteosarcomaen
dc.typeArtigo
Arquivos
Coleções
EPM - Artigos